Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

Peter A Argenta; Inhwa Um; Charlene Kay; David Harrison; Dana Faratian; Thanasak Sueblinvong; Melissa A Geller; Simon P Langdon

doi:10.1016/j.ygyno.2013.07.099

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

Peter A Argenta, Inhwa Um, Charlene Kay, David Harrison, Dana Faratian, Thanasak Sueblinvong, Melissa A Geller, Simon P Langdon

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Anti-estrogen therapy appears to have efficacy in a subset of ovarian cancers, as demonstrated in multiple phase II studies. Identifying sensitive patients early in treatment may allow for targeted, low-toxicity primary therapy or prevention of recurrence. We have previously demonstrated that the likelihood of response to letrozole could be improved by patient selection based on estrogen-pathway marker expression. We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist.

Original language	English
Pages (from-to)	368-373
Number of pages	6
Journal	Gynecologic Oncology
Volume	131
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2013.07.099
Publication status	Published - 30 Jul 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ygyno.2013.07.099

Cite this

@article{17b4e8ea964a43768434b43ca94b1fa2,

title = "Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer",

abstract = "Anti-estrogen therapy appears to have efficacy in a subset of ovarian cancers, as demonstrated in multiple phase II studies. Identifying sensitive patients early in treatment may allow for targeted, low-toxicity primary therapy or prevention of recurrence. We have previously demonstrated that the likelihood of response to letrozole could be improved by patient selection based on estrogen-pathway marker expression. We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist.",

author = "Argenta, \{Peter A\} and Inhwa Um and Charlene Kay and David Harrison and Dana Faratian and Thanasak Sueblinvong and Geller, \{Melissa A\} and Langdon, \{Simon P\}",

note = "M1 - Article",

year = "2013",

month = jul,

day = "30",

doi = "10.1016/j.ygyno.2013.07.099",

language = "English",

volume = "131",

pages = "368--373",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press/Elsevier ",

number = "2",

}

TY - JOUR

T1 - Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

AU - Argenta, Peter A

AU - Um, Inhwa

AU - Kay, Charlene

AU - Harrison, David

AU - Faratian, Dana

AU - Sueblinvong, Thanasak

AU - Geller, Melissa A

AU - Langdon, Simon P

N1 - M1 - Article

PY - 2013/7/30

Y1 - 2013/7/30

N2 - Anti-estrogen therapy appears to have efficacy in a subset of ovarian cancers, as demonstrated in multiple phase II studies. Identifying sensitive patients early in treatment may allow for targeted, low-toxicity primary therapy or prevention of recurrence. We have previously demonstrated that the likelihood of response to letrozole could be improved by patient selection based on estrogen-pathway marker expression. We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist.

AB - Anti-estrogen therapy appears to have efficacy in a subset of ovarian cancers, as demonstrated in multiple phase II studies. Identifying sensitive patients early in treatment may allow for targeted, low-toxicity primary therapy or prevention of recurrence. We have previously demonstrated that the likelihood of response to letrozole could be improved by patient selection based on estrogen-pathway marker expression. We sought to identify ovarian cancer biomarkers that might indicate sensitivity to fulvestrant, an estrogen receptor antagonist.

UR - https://www.scopus.com/pages/publications/84886098299

U2 - 10.1016/j.ygyno.2013.07.099

DO - 10.1016/j.ygyno.2013.07.099

M3 - Article

SN - 0090-8258

VL - 131

SP - 368

EP - 373

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 2

ER -

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this